Articles tagged with Blood Cancer
Researchers at Indiana University School of Medicine discovered a strong association between obesity and clonal hematopoiesis of indeterminate potential (CHIP), a blood condition that increases the risk of blood cancer. The study found that obesity causes inflammation, which can lead to rapid growth of mutated blood cells.
Research reveals both metabolically healthy and unhealthy obesity types linked to increased risk of various obesity-related cancers, with stronger association in metabolically unhealthy obesity. Metabolically unhealthy women face higher risks for endometrial, liver, and kidney cancers.
Researchers have engineered a new CRISPR-based drug candidate targeting E. coli directly while preserving the microbiome. The innovative treatment has shown promise in reducing E. coli burden in mice and is now in phase 1 clinical trials to treat blood cancer patients and prevent deadly infections.
A phase 2 clinical trial testing a treatment combining standard chemotherapy with azacitidine showed nearly 90% of patients with aggressive T-cell lymphoma achieved complete remission. The treatment, which targets gene-silencing marks on DNA, has an estimated two-year progression-free survival rate of 69.2%.
Researchers at ETH Zurich have developed a new method called pharmacoscopy to test treatment options for multiple myeloma patients. This high-throughput screening platform analyzes the reactions of cancer cells to various treatments, offering personalized therapeutic strategies.
Blinatumomab immunotherapy significantly improves the survival rate of babies with aggressive acute lymphoblastic leukemia (ALL), from 66% to 93%, while reducing side effects. The treatment is now standard for babies worldwide.
A study of 7807 children found no increased risk of brain tumours, leukemia, or lymphoma after a single CT scan. However, exposure to 4 or more scans before adulthood significantly increases the risk of intracranial tumours, leukemia, and non-Hodgkin lymphoma
A new method, CloneTracer, distinguishes between cancerous and healthy stem cells in acute myeloid leukemia (AML). The study reveals two distinct stem cell compartments and shows that progenitor cells respond better to therapy. This finding paves the way for developing new techniques to predict patient response to chemotherapy.
Researchers at Moffitt Cancer Center have identified a critical pathway in the development of MYC-driven lymphoma, involving the chemical modification of eIF5A with hypusine. Inhibiting this process prevents lymphoma development and progression in mouse models, offering new therapeutic strategies.
A UK Biobank study found that cancer survivors may be at long-term increased risk of cardiovascular disease, regardless of traditional risk factors. Those with previous breast or blood cancers were found to have the greatest risk, with significant changes in heart size and function detected on MRI scans.
Acute myeloid leukemia is a cancer that affects blood cells and can lead to infection, anemia, and easy bleeding. The Georgia Cancer Center has received a $2.3 million grant to study how cancer cells resist treatment and propose new options to improve patient survival.
Researchers at The Mount Sinai Hospital have created versatile disease models of acute myeloid leukemia (AML), allowing for accurate study of the cancer's progression and response to drugs. These models, derived from induced pluripotent stem cells, can mimic different stages of AML and are nearly identical to those found in patients.
Researchers at Vanderbilt University Medical Center have discovered a new way to measure the growth rate of precancerous clones of blood stem cells using a technique called PACER. The findings suggest that drugs targeting the gene TCL1A may be able to suppress clonal growth and associated cancers.
Researchers at St. Jude Children's Research Hospital developed a novel combination therapy approach that uses both BET and GSK3 inhibitors against KMT2A mutated leukemia, overcoming drug resistance without increasing toxicity. The approach was confirmed in cell lines and xenograft mouse models, and holds promise for further development.
A study by Linköping University researchers found that blood stem cells from leukemia patients remain in the bone marrow, but become defective over time, leading to long-term effects on blood formation. This discovery may explain why many leukemia survivors experience blood cell function disorders later in life.
Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.
A landmark study links iron regulation to a rare blood cancer, revealing that restricting iron access to the bone marrow can reduce red blood cell production in patients with polycythemia vera. Clinical trials are underway for a potential new treatment using a drug that controls iron regulation.
A new study reveals that patients with blood cancers experience significant improvement in their reported well-being after receiving CAR T-cell therapy. The therapy not only improves physical symptoms but also anxiety and depression symptoms.
A new study of over 200 people with premature aging syndromes caused by abnormally short telomeres suggests that chromosomal instability may not be the reason for increased cancer risk. Instead, immune system cells that age and die prematurely may play a role in cancer predisposition.
Researchers at the University of Missouri have developed a process for marking transplanted donor bone marrow cells, allowing them to target only cancerous cells. This breakthrough offers new hope for bone marrow transplant patients with blood cancers such as lymphoma and leukemia.
Researchers found that COVID-19 vaccination generates robust T cell responses in haematology patients, on par with healthy individuals. The study provides key insights for future immunisation strategies and shows that mRNA vaccines can elicit strong T cell immunity in patients with co-morbidities.
Researchers at the University of Wisconsin-Madison have identified a specific cell population, called CD4/CD8 double positive T cells, that causes graft-versus-host disease in bone marrow transplants. The team's findings may lead to targeted treatments and improved patient outcomes.
Scientists from USC Stem Cell laboratory discovered a mechanism linking leukemic mutations to varying disease potentials, identifying RNA splicing regulator Rbm25 as a critical factor. The study found that over-contributing clones of blood stem cells produce excessive myeloid cells, leading to potential leukemia development.
Researchers at Lund University discovered a novel mechanism linking RNA splicing to the development of leukemia in myelodysplastic syndrome patients. The study highlights the critical role of core spliceosome component SF3B1 and its regulation by N6-methyladenosine (m6A) modification, which provides a
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Researchers have identified two potential molecular targets, CSF1R and CD86, that can be used to develop CAR-T cells effective against acute myeloid leukemia. The study's findings demonstrate the potential of AI-assisted analysis in discovering new treatment options.
Children with Down syndrome are highly vulnerable to developing aggressive leukaemia due to a defect in the RUNX1 gene, which regulates blood cell formation. Researchers have identified a specific variant of the gene that promotes leukaemia development and discovered potential therapeutic approaches to correct this malfunction.
A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells. The therapy targets a DNA repair protein and shows promise in clinical trials.
Researchers developed a blood test to detect residual leukemia in AML patients before bone marrow transplant, showing that those with persistent mutations had higher risks of relapse and lower survival rates. The study supports ongoing research on precision medicine and personalized post-transplant care.
Researchers found that FABP5 is linked to more aggressive disease and poorer survival in multiple myeloma. Patients with higher FABP5 expression had significantly shorter time to disease progression and overall survival.
Researchers have discovered that the enzyme COASY plays a critical role in regulating red blood cell production in the bone marrow. Vitamin B5 supplementation and another metabolite increased the maturation of red blood cells in patients with Myelodysplastic syndromes, offering new hope for alternative treatments.
Researchers found that severe herpesvirus infections can strongly activate host cellular immunity, leading to a therapeutic effect on refractory adult T-cell leukemia/lymphoma. This activation may play an important role in the survival of patients with this intractable disease.
A study published in CANCER found that children with acute lymphoblastic leukemia living along the US-Mexico border had a lower five-year survival rate compared to those in non-border areas. The research highlights existing disparities in pediatric cancer outcomes, particularly among Hispanic and Black communities.
Researchers at VCU Massey Cancer Center have discovered a novel combination therapy that dramatically suppresses the growth of AML cells, including those resistant to venetoclax. The dual mTORC1/2 inhibitors synergistically enhance AML cell death when paired with venetoclax.
Researchers evaluate an integrated NGS system, delivering accurate diagnoses in under 24 hours and expanding targeted treatments available to patients with myeloid neoplasms. The assay identified 80-92% of genetic variants, demonstrating promising results for accelerating precision therapies.
Pusan National University researchers have identified a novel gene, SURF4, that regulates cell death and differentiation in acute myeloid leukemia (AML). The study found that suppressing SURF4 expression increases cell differentiation, cell death, and accumulation of ROS, leading to arrested tumor growth in mice.
Researchers found that female patients with diffuse large B-cell lymphoma treated in the afternoon had reduced mortality rates and cancer recurrence compared to those treated in the morning. The study suggests that timing chemotherapy delivery according to an individual's circadian clock may improve treatment outcomes.
A new study standardizes the use of optical genome mapping (OGM) for patients with blood cancers, demonstrating its potential as a frontline test for diagnosing hematologic malignancies. OGM outperforms existing tests in detecting cancer-causing gene variants and identifying additional information that can improve patient outcomes.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
Researchers at the University of Bergen have developed a method to predict cancer patient survival within hours of chemotherapy. By analyzing protein ERK1/2 levels in blood samples, they can identify patients who are responding or not responding to treatment, enabling early intervention.
Researchers at WashU Medicine identified a key transition point in the shift from chronic to aggressive leukemia, where blocking a molecule called DUSP6 prevents disease progression. Inhibiting this molecule also reduces inflammation in models of the disease.
A new software developed by researchers at Cold Spring Harbor Laboratory can accurately infers continental ancestry from tumor DNA and RNA. This technology has the potential to lead to more targeted and personalized cancer treatments by identifying genetic connections between cancer and race or ethnicity.
The study found that COVID-19 vaccination in patients with blood cancer activates a strong T cell response, providing protection against serious illness. Patients who form antibodies tend to produce high-quality antibodies capable of neutralizing different SARS-CoV-2 variants.
Researchers found that using tixagevimab-cilgavimab in blood cancer patients prevented moderate and severe COVID cases. The antibody provided protection but did not entirely prevent infection, highlighting the importance of additional safety measures.
The E1910 trial found that adding blinatumomab to standard front-line consolidation chemotherapy improved overall survival and kept most patients in remission. The treatment, which targets malignant B cells, demonstrated its effectiveness in patients with a good prognosis after an initial round of chemotherapy.
A unique clinical trial has achieved a remarkable 97% induction survival rate in patients with acute promyelocytic leukemia (APL) by providing a simplified treatment regimen and 24/7 support from APL experts. This collaborative care model, known as EA9131, significantly reduced early deaths and improved overall survival rates.
Modakafusp alfa has shown significant potential in combating multiple myeloma with 43% of patients experiencing a partial response. The treatment targets interferon in cells expressing CD38, a marker present on myeloma cells and immune cells.
Researchers have demonstrated successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous treatment. The novel fourth-generation CAR T therapy, huCART19-IL18, showed safe and potent antitumor efficacy in a Phase I clinical trial.
Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.
A new treatment protocol has been shown to significantly reduce the risk of aggressive childhood leukemia returning after chemotherapy. The ALL-11 protocol, which includes an extra year of maintenance chemotherapy for children with specific genetic mutations, has improved five-year survival rates and quality of life for these patients....
A Mount Sinai study found that certain inflammatory markers can predict which patients are more likely to respond to COVID-19 immunotherapies. The researchers identified a subtype of COVID-19 patients with hyperinflammation who could benefit from pacritinib, an anti-cancer drug.
Researchers have characterized the functional significance of DDX41 in molecular processes underlying cancer. The study reveals that DDX41 serves crucial functions in transcriptional processes, RNA splicing, and genomic integrity maintenance, which may hold significance in treating hematopoietic malignancies.
Scientists have developed a new technology that captures the key features of human bone marrow, allowing for the screening of multiple anti-cancer drugs and testing personalized treatments. The 'bone marrows in a dish' can support the survival of cells from patients with blood malignancies
USCF researchers have developed a new approach called CAR Pooling to compare different re-engineered T cells with varying molecular features. The screen revealed new and surprising receptors that make these therapeutic cells more powerful, promising a better treatment for blood cancers.
Researchers at UVA Cancer Center have identified interleukin-1 as a crucial contributor to the development of myelofibrosis, a potentially deadly bone marrow cancer. Targeting this cytokine could prevent myelofibrosis from progressing and spare bone marrow scarring.
Researchers found that overexpressing matriptase reduced myeloma cell proliferation and inhibited migration. Matriptase also blocked Src kinase activation, supporting its potential as a tumor suppressor in multiple myeloma. The study provides new insights into the role of matriptase in hematological malignancies.
Researchers have found therapies that can help patients with relapsed multiple myeloma who tried CAR-T therapy, including bispecific antibodies and other types of CAR-T cell therapy. The study analyzed 79 patients and found that stem cell transplants and other drug combinations showed some efficacy in these patients.
Scientists have discovered that leukemia cells can change their DNA read-out to evade treatment, making them harder to treat. The study identified key genetic changes that allow cancer cells to survive and relapse.
Researchers found that liquid biopsies can detect clonal haematopoiesis, a condition placing patients at higher risk of developing myelodysplastic syndrome or acute myeloid leukaemia. The study suggests that these patients should be referred for further evaluation to uncover actual risk and identify potential diagnostic pathways.
A recent study by Weill Cornell Medicine investigators found that corrupted endothelial cells can protect leukemia cells from chemotherapy drugs. The discovery has the potential to improve drug discovery programs and clinical trials for T-cell acute lymphoblastic leukemia (T-ALL) patients.